Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
This study has been completed.
Sponsor:
Bayer
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00927667
First received: June 23, 2009
Last updated: February 16, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The joint status (knees, ankles) of patients suffering from severe Hemophilia A (too little blood clotting factor VIII in blood) is evaluated in a single magnetic resonance imaging session. No study medication is given.
| Condition | Intervention | Phase |
|---|---|---|
|
Hemophilia A |
Procedure: No Drug |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | A Diagnostic Interventional, Controlled, Cross-sectional Evaluation of Joint Status Using Magnetic Resonance Imaging in Subjects With Severe Hemophilia A Treated With Primary Prophylaxis, Secondary Prophylaxis, or On-demand Therapy |
Resource links provided by NLM:
Further study details as provided by Bayer:
Primary Outcome Measures:
- Maximum ankle MRI score [ Time Frame: no timeframe (single visit, "snapshot" of the actual joint status) ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Total MRI score of the maximum index joint [ Time Frame: no timeframe (single visit, "snapshot" of the actual joint status) ] [ Designated as safety issue: No ]
- Number of bleeds in each index joint over previous 5 years [ Time Frame: no timeframe (medical history status) ] [ Designated as safety issue: No ]
- Number of total joint bleeds and their locations over previous 5 years [ Time Frame: no timeframe (medical history status) ] [ Designated as safety issue: No ]
- Physical joint score (Gilbert Score) [ Time Frame: no timeframe (single visit, "snapshot" of the actual joint status) ] [ Designated as safety issue: No ]
| Enrollment: | 156 |
| Study Start Date: | June 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Procedure: No Drug
Patients have received primary FVIII prophylaxis (started < 2 years of age)
|
| Experimental: Arm 2 |
Procedure: No Drug
Patients have received secondary FVIII prophylaxis (started 2 - < 6 years of age)
|
| Experimental: Arm 3 |
Procedure: No Drug
Patients have received secondary FVIII prophylaxis (started 6 - < 12 years of age)
|
| Experimental: Arm 4 |
Procedure: No Drug
Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
|
| Experimental: Arm 5 |
Procedure: No Drug
Patients have received on-demand therapy
|
Eligibility| Ages Eligible for Study: | 12 Years to 35 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males aged 12 - 35 years
- Severe hemophilia A ( < 1 % FVIII:C)
- No history of Factor VIII inhibitory antibody
- For prophylaxis groups, having received at least two prophylactic infusions per week for 45 weeks per year for the prevention of bleeding without relevant interruption and continuing until the present.
- Complete documentation of joints bleeds and their locations prior to start of prophylaxis,
- Bleeding history and/or treatments received during the last 5 years documented in the subjects medical records.
- For the on-demand subjects > 12 bleeds/year in the last 5 years.
- Written informed consent by subject and parent/legal representative, if < 18 years
Exclusion Criteria:
- Individuals with other coagulopathies (e.g., von Willebrand disease)
- HIV seropositive subjects
- Individuals for whom the most clinically severe joint is not one of the 4 index joints (ankle, knee)
- HCV seropositive individuals who underwent interferon therapy during the last 12 months
- Individuals for whom high-magnetic exposure is contraindicated (see section 7.1)
- Synovectomy performed within the six months prior to investigation enrollment or orthopedic surgery planned to be performed within the investigation period
- Joint replacement
- For the on-demand treatment group, any period greater than 8 consecutive months having received >/= 50 IU per kg per week Factor VIII for the prevention of bleeding
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00927667
Locations
| Germany | |
| Heidelberg, Baden-Württemberg, Germany, 69123 | |
| Bonn, Nordrhein-Westfalen, Germany, 53105 | |
| Münster, Nordrhein-Westfalen, Germany, 48143 | |
| Magdeburg, Sachsen-Anhalt, Germany, 39112 | |
| Greece | |
| Athens, Greece, 115 27 | |
| Italy | |
| Milano, Italy, 20122 | |
| Padova, Italy, 35121 | |
| Parma, Italy, 43100 | |
| Roma, Italy, 00161 | |
| Spain | |
| A Coruña, Spain, 15006 | |
| Valencia, Spain, 46026 | |
| Sweden | |
| Malmö, Sweden, 205 02 | |
| Stockholm, Sweden, 171 76 | |
| United Kingdom | |
| Canterbury, Kent, United Kingdom, CT1 3NG | |
| London, United Kingdom, NW3 2QG | |
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Head Clinical Pharmacology, Bayer Healthcare AG |
| ClinicalTrials.gov Identifier: | NCT00927667 History of Changes |
| Other Study ID Numbers: | 12948, 2009-010147-14 |
| Study First Received: | June 23, 2009 |
| Last Updated: | February 16, 2013 |
| Health Authority: | Germany:Paul-Ehrlich-Institut, Langen |
Keywords provided by Bayer:
|
Hemophilia A Joint Status Bleeds Magnetic Resonce Imaging |
Additional relevant MeSH terms:
|
Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Hemorrhagic Disorders |
Genetic Diseases, Inborn Factor VIII Coagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013